Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes (Car-Te-Cell)

Civil Hospices of Lyon

Status: Enrolling

Conditions: Paraneoplastic Neurological Syndrome; Autoimmune Encephalitis

Treatments: Biological: Genetic and immunology tests

Study type: Observational

Funder types: Other

Identifiers

NCT05772611

788

Details and patient eligibility

About

Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients.

Enrollment: 180 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with neurological disorder
• Patient with antibodies or not in sera or CSF

Exclusion criteria

• No available clinical data

Trial design

180 participants in 3 patient groups

Antibody characterized

Description:

Patients with well-characterized antibody (HU, YO, RI, CASPR2, NMDAr, GAD, ...)

Treatment:

Biological: Genetic and immunology tests

Atypical

Description:

Patients with atypical antibody

Treatment:

Biological: Genetic and immunology tests

Without antibody

Description:

Patients without antibody

Treatment:

Biological: Genetic and immunology tests